Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.50 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2722128 | 0.89 | MEN1 (0.73) | MEN1KMT2ARECQLPOLBMAPT | |
| SCHEMBL8380032 | 0.87 | POLB (0.69) | MEN1KMT2ARECQLPOLBMAPT | |
| SCHEMBL8374386 | 0.81 | MEN1 (0.64) | MEN1KMT2ARECQLPOLBMAPT | |
| SCHEMBL710603 | 0.80 | LMNA (0.57) | MEN1KMT2ARECQLPOLBMAPT | |
| SCHEMBL10246413 | 0.79 | KDM4E (0.59) | MEN1KMT2AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL18496690 | 0.79 | MEN1 (0.60) | MEN1KMT2ARECQLPOLBMAPT | |
| SCHEMBL29727627 | 0.79 | MEN1 (0.60) | MEN1KMT2ARECQLPOLBMAPT | |
| SCHEMBL229926 | 0.79 | MEN1 (0.57) | MEN1KMT2ARECQLPOLBMAPT | |
| SCHEMBL27484718 | 0.79 | POLB (0.55) | MEN1KMT2ARECQLPOLBMAPT | |
| SCHEMBL9799681 | 0.78 | MEN1 (0.79) | MEN1KMT2APOLBMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | MTPN, CHRNA7, CHRNA10 | MEN1 3294/4885KMT2A 3851/4885RECQL 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.